Literature DB >> 11986039

The adolescent with an inborn error of metabolism: medical issues and transition to adulthood.

Gregory M Enns1, Wendy Packman.   

Abstract

As patients with inborn errors of metabolism survive longer, understanding of potential medical and psychiatric complications adolescence and adulthood has increased. In general, detailed therapeutic guidelines for specific metabolic disorders are not available, and medical management must be tailored to the individual patient. Close interaction between the biochemical genetics clinic staff, primary care physician, mental health professional, and other specialists is necessary to formulate an integrated care plan. The education of the patient and family is a critical function of the biochemical genetics clinic, and transition from dependence on parents or other care providers to full independence is gradual. The ultimate goal is for the patient to have the essential knowledge and motivation required to cope responsibly with dietary and medical therapeutic regimens by adolescence or early adulthood. Specific illustrative inborn errors of metabolism are discussed (aminoacidemias, urea cycle defects, organic acidemias, fatty acid oxidation defects, disorders of carbohydrate metabolism, lysosomal storage disorders) in light of potential problems encountered in adolescence and adulthood, including issues involving pregnancy and long-term medical, psychosocial, and psychiatric complications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986039

Source DB:  PubMed          Journal:  Adolesc Med        ISSN: 1041-3499


  11 in total

1.  A series of pregnancies in women with inherited metabolic disease.

Authors:  Janneke G Langendonk; Jonathan C P Roos; Lindsay Angus; Monique Williams; François P J Karstens; Johannes B C de Klerk; Charlé Maritz; Tawfeg Ben-Omran; Catherine Williamson; Robin H Lachmann; Elaine Murphy
Journal:  J Inherit Metab Dis       Date:  2011-09-15       Impact factor: 4.982

2.  Psychological complications of patients with Gaucher disease.

Authors:  W Packman; T Wilson Crosbie; A Riesner; C Fairley; S Packman
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Long-term needs of adult patients with organic acidaemias: outcome and prognostic factors.

Authors:  E Martín-Hernández; P J Lee; A Micciche; S Grunewald; R H Lachmann
Journal:  J Inherit Metab Dis       Date:  2009-07-23       Impact factor: 4.982

4.  Psychological aspects of patients with Fabry disease.

Authors:  T Wilson Crosbie; Wendy Packman; S Packman
Journal:  J Inherit Metab Dis       Date:  2009-10-31       Impact factor: 4.982

5.  Psychosocial issues in families affected by maple syrup urine disease.

Authors:  Wendy Packman; Shelly L Henderson; Indira Mehta; Rama Ronen; Dean Danner; Beth Chesterman; Seymour Packman
Journal:  J Genet Couns       Date:  2007-08-17       Impact factor: 2.537

Review 6.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

Review 7.  Maple syrup urine disease: mechanisms and management.

Authors:  Patrick R Blackburn; Jennifer M Gass; Filippo Pinto E Vairo; Kristen M Farnham; Herjot K Atwal; Sarah Macklin; Eric W Klee; Paldeep S Atwal
Journal:  Appl Clin Genet       Date:  2017-09-06

8.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

9.  Environmental influences on familial discordance of phenotype in people with homocystinuria: a case report.

Authors:  Francois Maillot; Jan P Kraus; Philip J Lee
Journal:  J Med Case Rep       Date:  2008-04-20

10.  Ten years of specialized adult care for phenylketonuria - a single-centre experience.

Authors:  Ulrike Mütze; Alena Gerlinde Thiele; Christoph Baerwald; Uta Ceglarek; Wieland Kiess; Skadi Beblo
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.